A new ADC biotech looks to re­vive se­cre­tive plat­form, se­cures Big VC back­ing

With many com­pa­nies work­ing with an­ti­body-drug con­ju­gates in can­cer, the newest one has two sub­stan­tial back­ers and is look­ing to re­vi­tal­ize an old plat­form. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER